36,033 research outputs found
DataSheet1_Integrated Network Pharmacology Analysis and Experimental Validation to Investigate the Mechanism of Zhi-Zi-Hou-Po Decoction in Depression.docx
No full textZhi-Zi-Hou-Po Decoction (ZZHPD) is a well-known traditional Chinese medicine (TCM) that has been widely used in depression. However, the antidepressant mechanism of ZZHPD has not yet been fully elucidated. The purpose of this study was to explore the pharmacological mechanisms of ZZHPD acting on depression by combining ultra flow liquid chromatography with quadrupole time-of-flight mass spectrometry (UFLC-Q-TOF/MS) and network pharmacology strategy. The chemical components of ZZHPD were identified using UFLC-Q-TOF/MS, while the potential drug targets and depression-related targets were collected from databases on the basis of the identified compounds of ZZHPD. Protein-protein interaction (PPI) network, gene ontology (GO), and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were used to unravel potential antidepressant mechanisms. The predicted antidepressant targets from the pharmacology-based analysis were further verified in vivo. As a result, a total of 31 chemical compounds were identified by UFLC-Q-TOF/MS; 514 promising drug targets were mined by using the Swiss Target Prediction; and 527 depression-related target genes were pinpointed by the GeneCards and OMIM databases. STRING database and Cytoscape’s topological analysis revealed 80 potential targets related to the antidepressant mechanism of ZZHPD. The KEGG pathway analysis revealed that the antidepressant targets of ZZHPD were mainly involved in dopaminergic synapse, serotonin synapse, cAMP, and mTOR signaling pathways. Furthermore, based on the animal model of depression induced by chronic corticosterone, the regulatory effects of ZZHPD on the expression of MAOA, MAOB, DRD2, CREBBP, AKT1, MAPK1, HTR1A, and GRIN2B mRNA levels as well as the cAMP signaling pathway and monoaminergic metabolism were experimentally verified in rats. Our study revealed that ZZHPD is expounded to target various genes and pathways to perform its antidepressant effect.</p
DataSheet2_Integrated Network Pharmacology Analysis and Experimental Validation to Investigate the Mechanism of Zhi-Zi-Hou-Po Decoction in Depression.docx
No full textZhi-Zi-Hou-Po Decoction (ZZHPD) is a well-known traditional Chinese medicine (TCM) that has been widely used in depression. However, the antidepressant mechanism of ZZHPD has not yet been fully elucidated. The purpose of this study was to explore the pharmacological mechanisms of ZZHPD acting on depression by combining ultra flow liquid chromatography with quadrupole time-of-flight mass spectrometry (UFLC-Q-TOF/MS) and network pharmacology strategy. The chemical components of ZZHPD were identified using UFLC-Q-TOF/MS, while the potential drug targets and depression-related targets were collected from databases on the basis of the identified compounds of ZZHPD. Protein-protein interaction (PPI) network, gene ontology (GO), and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were used to unravel potential antidepressant mechanisms. The predicted antidepressant targets from the pharmacology-based analysis were further verified in vivo. As a result, a total of 31 chemical compounds were identified by UFLC-Q-TOF/MS; 514 promising drug targets were mined by using the Swiss Target Prediction; and 527 depression-related target genes were pinpointed by the GeneCards and OMIM databases. STRING database and Cytoscape’s topological analysis revealed 80 potential targets related to the antidepressant mechanism of ZZHPD. The KEGG pathway analysis revealed that the antidepressant targets of ZZHPD were mainly involved in dopaminergic synapse, serotonin synapse, cAMP, and mTOR signaling pathways. Furthermore, based on the animal model of depression induced by chronic corticosterone, the regulatory effects of ZZHPD on the expression of MAOA, MAOB, DRD2, CREBBP, AKT1, MAPK1, HTR1A, and GRIN2B mRNA levels as well as the cAMP signaling pathway and monoaminergic metabolism were experimentally verified in rats. Our study revealed that ZZHPD is expounded to target various genes and pathways to perform its antidepressant effect.</p
Table2_Discovery of the Potential Novel Pharmacodynamic Substances From Zhi-Zi-Hou-Po Decoction Based on the Concept of Co-Decoction Reaction and Analysis Strategy.DOCX
No full textBackground: Zhi-Zi-Hou-Po Decoction (ZZHPD), a classic traditional Chinese medicine (TCM) formula, is clinically used to treat insomnia and depression. The analysis strategy based on the concept of co-decoction of TCM is helpful to analyse the effective substances of TCM formula in depth.Aim of the study: This manuscript intends to take ZZHPD as a model sample to explore the phenomenon of co-decoction of complex formula in the combination of liquid chromatography-mass spectrometry (LC-MS) technology, data analysis, and molecular docking.Materials and methods: In the current research, an innovative LC-MS method has been established to study the active ingredients in ZZHPD, and to identify the ingredients absorbed into the blood and brain tissues of mice. And molecular docking was used to study the binding pattern and affinities of known compounds of the brain tissue toward insomnia related proteins.Results: Based on new processing methods and analysis strategies, 106 chemical components were identified in ZZHPD, including 28 blood components and 18 brain components. Then, by comparing the different compounds in the co-decoction and single decoction, it was surprisingly found that 125 new ingredients were produced during the co-decoction, 2 of which were absorbed into the blood and 1 of which was absorbed into brain tissue. Ultimately, molecular docking studies showed that 18 brain components of ZZHPD had favourable binding conformation and affinity with GABA, serotonin and melatonin receptors. The docking results of GABRA1 with naringenin and hesperidin, HCRTR1 with naringenin-7-O-glucoside, poncirenin and genipin 1-gentiobioside, and luteolin with SLC6A4, GLO1, MAOB and MTNR1A may clarify the mechanism of action of ZZHPD in treating insomnia and depression.Conclusion: Our study may provide new ideas for further exploring the effective substances in ZZHPD.</p
Table1_Discovery of the Potential Novel Pharmacodynamic Substances From Zhi-Zi-Hou-Po Decoction Based on the Concept of Co-Decoction Reaction and Analysis Strategy.DOCX
No full textBackground: Zhi-Zi-Hou-Po Decoction (ZZHPD), a classic traditional Chinese medicine (TCM) formula, is clinically used to treat insomnia and depression. The analysis strategy based on the concept of co-decoction of TCM is helpful to analyse the effective substances of TCM formula in depth.Aim of the study: This manuscript intends to take ZZHPD as a model sample to explore the phenomenon of co-decoction of complex formula in the combination of liquid chromatography-mass spectrometry (LC-MS) technology, data analysis, and molecular docking.Materials and methods: In the current research, an innovative LC-MS method has been established to study the active ingredients in ZZHPD, and to identify the ingredients absorbed into the blood and brain tissues of mice. And molecular docking was used to study the binding pattern and affinities of known compounds of the brain tissue toward insomnia related proteins.Results: Based on new processing methods and analysis strategies, 106 chemical components were identified in ZZHPD, including 28 blood components and 18 brain components. Then, by comparing the different compounds in the co-decoction and single decoction, it was surprisingly found that 125 new ingredients were produced during the co-decoction, 2 of which were absorbed into the blood and 1 of which was absorbed into brain tissue. Ultimately, molecular docking studies showed that 18 brain components of ZZHPD had favourable binding conformation and affinity with GABA, serotonin and melatonin receptors. The docking results of GABRA1 with naringenin and hesperidin, HCRTR1 with naringenin-7-O-glucoside, poncirenin and genipin 1-gentiobioside, and luteolin with SLC6A4, GLO1, MAOB and MTNR1A may clarify the mechanism of action of ZZHPD in treating insomnia and depression.Conclusion: Our study may provide new ideas for further exploring the effective substances in ZZHPD.</p
Fig. 4 in Guaiane-type sesquiterpenoids from the roots of Stellera chamaejasme L. and their neuroprotective activities
No full textFig. 4. Correlation coefficients and DP4+ analysis between experimental and calculated 13C NMR chemical shifts of 4S*,5S*,8R*-3a and 4S*,5S*,8S*-3b.Published as part of Cheng, Zhuo-Yang, Hou, Zi-Lin, Ren, Jing-Xian, Zhang, Ding-Ding, Lin, Bin, Huang, Xiao-Xiao & Song, Shao-Jiang, 2021, Guaiane-type sesquiterpenoids from the roots of Stellera chamaejasme L. and their neuroprotective activities, pp. 1-10 in Phytochemistry (112628) 183 on page 4, DOI: 10.1016/j.phytochem.2020.112628, http://zenodo.org/record/829167
Fig. 2. Key HMBC correlations for compounds 1 and 2 in Insight into tetrahydrofuran lignans from Isatis indigotica fortune with neuroprotective and acetylcholinesterase inhibitor activity
No full textFig. 2. Key HMBC correlations for compounds 1 and 2.Published as part of Xi, Yu-Fei, Bai, Ming, Zhang, Xin, Hou, Zi-Lin, Lin, Bin, Yao, Guo-Dong, Lou, Li-Li, Wang, Xiao-Bo, Song, Shao-Jiang & Huang, Xiao-Xiao, 2023, Insight into tetrahydrofuran lignans from Isatis indigotica fortune with neuroprotective and acetylcholinesterase inhibitor activity, pp. 113609 in Phytochemistry (113609) 208 on page 3, DOI: 10.1016/j.phytochem.2023.113609, http://zenodo.org/record/816072
Fig. 3 in Insight into tetrahydrofuran lignans from Isatis indigotica fortune with neuroprotective and acetylcholinesterase inhibitor activity
No full textFig. 3. The key NOESY correlations of compounds 1 and 2.Published as part of Xi, Yu-Fei, Bai, Ming, Zhang, Xin, Hou, Zi-Lin, Lin, Bin, Yao, Guo-Dong, Lou, Li-Li, Wang, Xiao-Bo, Song, Shao-Jiang & Huang, Xiao-Xiao, 2023, Insight into tetrahydrofuran lignans from Isatis indigotica fortune with neuroprotective and acetylcholinesterase inhibitor activity, pp. 113609 in Phytochemistry (113609) 208 on page 3, DOI: 10.1016/j.phytochem.2023.113609, http://zenodo.org/record/816072
Li han lin quan ji: si shi er juan, mu lu si juan, nian pu. v.1
No full text[李白].綫裝, 1函.框20.3x14.8公分, 9行18字, 小字雙行同. 白口, 左右雙邊, 單白魚尾. 版心中鐫"李集"及卷次, 下鐫葉次.書根印有"李翰林集"前有王樨登序, 李陽冰《李翰林詩序》, 樂史《別集序》, 宋敏求後序, 曾鞏後序, 毛漸題跋.書中樂史《別集序》載"李翰林歌詩李陽冰纂為草堂集十卷史又別收歌詩十卷與草堂集互有得失因校勘排為二十卷號曰李翰林集"With: 李翰林年譜 / 薛仲邕編 ; 舊唐書列傳 ; 新唐書列傳 ; 李翰林墓誌銘 / 李華 ; 碣記 / 劉全 ; 碑陰記 / 蘇軾.Xian zhuang, 1 han.Kuang 20.3 x 14.8 gong fen, 9 hang 18 zi, xiao zi shuang hang tong. Bai kou, zuo you shuang bian, dan bai yu wei. Ban xin zhong juan "Li ji"ji juan ci, xia juan ye ci.Shu gen yin you "Li han lin ji"Qian you Wang Xideng xu, Li Yangbing "Li han lin shi xu", Yue Shi "Bie ji xu", Song Minqiu hou xu, Zeng Gong hou xu, Mao Jian ti ba.Shu zhong Yue Shi "Bie ji xu" zai "Li han lin ge shi Li Yangbing zuan wei Cao tang ji shi juan shi you bie shou ge shi shi juan yu Cao tang ji hu you de shi yin jiao kan pai wei er shi juan hao yue Li han lin ji"[Li Bai].With: Li han lin nian pu / Xue Zhongyong bian ; Jiu Tang shu lie zhuan ; Xin Tang shu lie zhuan ; Li han lin mu zhi ming / Li Hua ; Jie ji / Liu Quan ; Bei yin ji / Su Shi
Basalys sinensis Hou & Xu 2016, sp. nov.
No full textBasalys sinensis sp. nov. (Fig. 1) Diagnosis. Head flattened and subrectangular in dorsal view; scape markedly widened at middle; antenna club 3-segmented. Description. Female (Holotype). Body length 0.89 mm. Fore wing length 0.46 mm. Colour. Head black. Antennae brown, with clubs blackish-brown. Mandibles reddish-brown. Mesosoma blackishbrown. Fore and hind wings hyaline, veins brown. Legs brown, with coxae, trochanters and first to fourth tarsi yellowish-brown. Metasoma blackish-brown. Head. Head smooth and shining, with scattered hairs; subrectangular, 1.08 times as long as wide in dorsal view (8.1: 7.5); 1.65 times as long as high in lateral view (8.1: 4.8). Clypeus convex. Antennal shelf well developed, prominent anteriorly in lateral view. Antenna 12-segmented; club 3-segmented, strongly abrupt dorsally; relative ratio of length to width as follows: A1(11.0: 3.0), A2(3.0: 2.0), A3(1.0: 1.0), A4(1.0: 1.0), A5(1.0: 1.0), A6(1.0: 1.5), A7(1.0: 1.5), A8(1.0: 2.0), A9(1.5: 2.0), A10(4.0: 4.0), A11(4.0: 3.5), A12(4.5: 3.5). A1 markedly widened at middle. Toruli at level of lower margin of eye. Eye oval, with scattered hairs; 1.67 times as long as wide (9.5: 5.7); 1.67 times as long as malar space (9.5: 5.7). POL: OOL=2.0: 3.0. Temple rounded in dorsal view, 0.62 times as long as eye (5.1: 8.2). Postgenal cushion with tufts of hairs. Occipital carina complete. Mesosoma. Pronotum with scattered hairs; with anterior margin straight in dorsal view. Epomium absent. Propleuron densely hairy. Mesoscutum smooth and shining, slightly convex, with scattered hairs; 0.64 times as long as wide (6.2: 9.8). Notauli absent. Mesoscutellum with distinct transverse basal fovea. mesoscutellar disc subquadrate, smooth and shining, with scattered hairs, predominantly flat. Mesopleuron flat, smooth and shining, with scattered hairs. Sternaulus absent. Dorsellum smooth and shining, with scattered hairs. Metapleuron rugulose and densely hairy. Propodeum 0.57 times as long as wide (2.6: 4.6), with strong longitudinal median keel and well defined pilca. Area between median keel and plica predominantly glabrous and smooth. Fore wing fully developed, surpassing apex of metasoma. Fore wing venation distinctly surpassing basal third of wing length, with stigmal vein moderate developed, and basal vein straight, perpendicular to but never contiguous with submarginal vein. Legs slender, with femora and tibia clavate; fore tibia without dorsal spine apically; tarsi not compressed. Metasoma. Petiole cylindrical, densely hairy, 1.20 times as long as wide in dorsal view (6.6: 5.5); 1.14 times as long as high in lateral view (6.6: 5.8); with some longitudinal keels on dorsal surface. Syntergite slightly convex in lateral view. Syntergite with anterior margin straight and complete, not excised medially. Metasoma moderately pointed apically. Male. Unknown. Material examined. Holotype ♂, China, Yunnan, Zhaotong, Yongshan, Huanghua, V–X.2012, leg. Shiwen Yang (SCAU). Paratypes. 10♂, Yunnan, Zhaotong, Yongshan, Huanghua, VIII–X.2012, leg. Shiwen Yang; 10♂, Yunnan, Kaiyuan, VIII.2014, leg. Zi Hou (SCAU). Biology. Unknown. Distribution. China (Yunnan). Remarks. This new species resembles Basalys unicus Rajmohana & Narendran, 2006 from India, but it can be separated from the latter by: antenna 12-segmented (11-segmented in B. unicus); head distinctly long than high in lateral view (almost quadrate in B. unicus); notauli absent (present but faint in B. unicus). Etymology. The new species is named after the type locality, China.Published as part of Hou, Zi & Xu, Zaifu, 2016, First record of the genus Basalys Westwood, 1833 (Hymenoptera: Diapriidae) from China, with descriptions of two new species, pp. 337-341 in Zoological Systematics 41 (3) on page 338, DOI: 10.11865/zs.201639, http://zenodo.org/record/536476
First record of the genus Basalys Westwood, 1833 (Hymenoptera: Diapriidae) from China, with descriptions of two new species
No full textHou, Zi, Xu, Zaifu (2016): First record of the genus Basalys Westwood, 1833 (Hymenoptera: Diapriidae) from China, with descriptions of two new species. Zoological Systematics 41 (3): 337-341, DOI: 10.11865/zs.20163
- …
